Clinical Utility of FDG-PET in Detecting Head and Neck Tumors

Positron emission tomography (PET) using F-18-fluoro-2-deoxy-d-glucose(F-18-FDG) is gaining acceptance as a useful imaging method for head and neck tumors. Results of 59 PET scans done on 45 patients with head and neck tumors were evaluated retrospectively. Thirty-six patients had prior treatment consisting of surgery, radiation therapy, chemotherapy, or a combination of these modalities. PET results were compared to computed tomography $\text{CT}\text{N}\text{= 38}$ and magnetic resonance imaging $\text{MRI}\text{N}\text{= 14}$ results and validated by histologic findings or survival. PET identified 36 out of 37 tumors (sensitivity 97%) and 18 of 22 benign processes (specificity 82%). Tumor was ruled out in 18 out of 19 patients. For CT, the sensitivity was 80% (20/25) and specificity was 31% (4/13). FDG-PET facilitates differentiation of recurrent head and neck tumors from treatment related changes sometimes difficult to characterize by CT or MRI and may have a significant impact on the management of patients reducing morbidity and costs.